These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 3978663)

  • 1. N-methylformamide-induced hypophosphatemia.
    Sternberg CN; Yagoda A
    Cancer Treat Rep; 1985 Mar; 69(3):343-4. PubMed ID: 3978663
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II trial of N-methylformamide for advanced renal cell carcinoma.
    Sternberg CN; Yagoda A; Scher HI; Hollander P
    Cancer Treat Rep; 1986 May; 70(5):681-2. PubMed ID: 3708620
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II trial of N-methylformamide in advanced renal cancer.
    Abrams JS; Tait N; Silva H; Eisenberger M; Van Echo DA; Olver IN; Aisner J
    Am J Clin Oncol; 1989 Feb; 12(1):41-2. PubMed ID: 2912020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of N-methylformamide in pediatric patients with refractory leukemias.
    Murphy SB; Mirro J; Pui CH; Pratt CB
    Cancer Treat Rep; 1987 Dec; 71(12):1299-300. PubMed ID: 3690543
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase I study of N-methylformamide in patients with advanced cancer.
    Ettinger DS; Orr DW; Rice AP; Donehower RC
    Cancer Treat Rep; 1985 May; 69(5):489-93. PubMed ID: 4005871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of N-methylformamide.
    McVie JG; ten Bokkel Huinink WW; Simonetti G; Dubbelman R
    Cancer Treat Rep; 1984 Apr; 68(4):607-10. PubMed ID: 6325001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
    Ramsey S; Aitchison M
    J Urol; 2005 Dec; 174(6):2422-3. PubMed ID: 16280863
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer.
    Ettinger DS; Finkelstein DM; Abeloff MD; Chang YC; Smith TJ; Oken MM; Ruckdeschel JC
    Invest New Drugs; 1990 May; 8(2):183-5. PubMed ID: 2166720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.
    Kirkwood JM; Tarhini AA
    J Clin Oncol; 2009 Jun; 27(16):2583-5. PubMed ID: 19364958
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II trial of elliptinium in advanced renal cell carcinoma.
    Caillé P; Mondesir JM; Droz JP; Kerbrat P; Goodman A; Ducret JP; Theodore C; Spielman M; Rouëssé J; Amiel JL
    Cancer Treat Rep; 1985; 69(7-8):901-2. PubMed ID: 4016798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
    Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
    J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of procollagen type 1 amino-terminal propeptide in patients with renal cell carcinoma.
    Klepzig M; Sauer-Eppel H; Jonas D; Oremek GM
    Anticancer Res; 2008; 28(4C):2443-6. PubMed ID: 18751432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A preliminary study of combination therapy of vinblastine and nicardipine in patients with advanced renal cell carcinoma].
    Masuda M
    Nihon Hinyokika Gakkai Zasshi; 1987 Nov; 78(11):1890-4. PubMed ID: 3450928
    [No Abstract]   [Full Text] [Related]  

  • 14. Sequential therapies in metastatic renal cell carcinoma: option or strategy?
    Bracarda S; De Simone V
    Eur Urol; 2008 Dec; 54(6):1219-20; discussion 1221-2. PubMed ID: 18778889
    [No Abstract]   [Full Text] [Related]  

  • 15. Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice.
    Rakhit A; Yeon MM; Ferrante J; Fettner S; Nadeau R; Motzer R; Bukowski R; Carvajal DM; Wilkinson VL; Presky DH; Magram J; Gately MK
    Clin Pharmacol Ther; 1999 Jun; 65(6):615-29. PubMed ID: 10391667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic chemotherapy for advanced renal cell carcinoma.
    Yagoda A; Petrylak D; Thompson S
    Urol Clin North Am; 1993 May; 20(2):303-21. PubMed ID: 8493752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon-alpha: course and relationship with psychiatric status.
    Van Gool AR; Verkerk R; Fekkes D; Bannink M; Sleijfer S; Kruit WH; van der Holt B; Scharpé S; Eggermont AM; Stoter G; Hengeveld MW
    Psychiatry Clin Neurosci; 2008 Oct; 62(5):597-602. PubMed ID: 18950381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type-I interferon receptor expression: its circadian rhythm and downregulation after interferon-alpha administration in peripheral blood cells from renal cancer patients.
    Shiba M; Nonomura N; Nakai Y; Nakayama M; Takayama H; Inoue H; Tsujimura A; Nishimura K; Okuyama A
    Int J Urol; 2009 Apr; 16(4):356-9. PubMed ID: 19302507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
    Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL
    Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial comment on: Lower plasma adiponectin levels are associated with larger tumor size and metastasis in clear-cell carcinoma of the kidney.
    Zigeuner R
    Eur Urol; 2008 Oct; 54(4):873-4. PubMed ID: 18343563
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.